Zura Bio appoints Eisner and Nirula to board; Graham resigns

Zura Bio Ltd

Neil Graham resigned from Zura's board effective Feb 21, 2026; departure not due to any disagreement.
Mark Eisner (Vir Bio CMO) and Ajay Nirula (Recludix Pharma EVP R&D, former Lilly exec) appointed as directors.
Each new director receives $40k annual cash retainer and initial option for up to 51,000 shares (or $200k value).
Board changes come as Zura advances Phase 2 tibulizumab trials in hidradenitis suppurativa and systemic sclerosis.

item 5.02 item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001104659-26-018312
form_type: 8-K
ticker: ZURA
cik: 0001855644
company_name: Zura Bio Ltd
filed_at: 2026-02-23T23:59:59+00:00
discovered_at: 2026-05-14T18:02:36.567444+00:00
generated_at: 2026-05-16T01:16:14.630009+00:00
sec_items: ["5.02", "7.01", "9.01"]
event_type: leadership
sentiment: neutral
materiality_score: 0.55
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001104659-26-018312
json_url: https://secwatch.observer/filing/0001104659-26-018312.json
markdown_url: https://secwatch.observer/filing/0001104659-26-018312.md
text_url: https://secwatch.observer/filing/0001104659-26-018312.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1855644/000110465926018312/0001104659-26-018312-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1855644/000110465926018312/tm267035d1_8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001104659-26-018312

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.